HR and breast carcinoma: In this study, PALB2 carriers were more often to be detected in patients with HER2-negative breast cancer than non-carriers (83.3% vs. 70.2%), and HR+/HER2- breast cancer was the predominant molecular subtype among PALB2 carriers, accounting for 75%, whereas TNBC accounted for only 8.3%.